References in periodicals archive ?
The FDA subsequently approved the use of simeprevir in combination with sofosbuvir for patients with genotype 1 chronic HCV infection in 2014 (FDA, 2017), and the combination of daclatasvir and sofosbuvir in 2015 for genotype 3 chronic HCV infection (CDC, 2017).
D'Avolio, A UHPLC-MS/MS Method for the Quantification of Direct Antiviral Agents Simeprevir, Daclatasvir, Ledipasvir, Sofosbuvir/GS-331007, Dasabuvir, Ombitasvir and Paritaprevir, Together with Ritonavir, in Human Plasma, J.
Medivir AB (STO: MVIR) announced on Sunday that Janssen Pharmaceuticals Inc (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen's assessment of market demand.
164: Sofosbuvir, daclatasvir e simeprevir para o tratamento da hepatite viral C cronica.
Comment: Protease inhibitors such as simeprevir, when used in combination with PEG IFN and ribavirin, produce an SVR rate of about 90% in patients with chronic HCV genotype lb who have the rs8099917 genotype TT of the IL28B gene.
Under this agreement, Medivir will receive royalties on sales of all simeprevir containing products in the Nordics in exchange, as it already does in the rest of the world, as well as additional performance based milestones totalling up to approximately EUR6m based on certain sales targets for the Nordics of a combination product containing simeprevir.
Boceprevir, telaprevir, and simeprevir inhibit CYP3A4 to varying degrees and therefore could affect psychotropic medications metabolized by this enzyme.
He cited a case of a patient who took simeprevir and developed photodistributed lichenoid eruptions (J Cutan Pathol.
The last treatment I undertook was 2 years ago with a simple combination of simeprevir and sofosbuvir (Sovaldi), two pills per day for 3 months.
HCV Genotype 1: Harvoni, Viekira Pak, Daclatasvir and Simeprevir are the approved DAAs against genotype 1; as these agents are still not available in Pakistan, therefore the only option left for these patients is SOF+RBV+ PEG-IFN for 12 weeks.
Para noviembre del 2013, la FDA acepto el uso de simeprevir en combinacion con IFN-PEG y RBV (16).
In late 2013, simeprevir and sofosbuvir received FDA approval for use in the treatment of FICV; a year later, the combinations of sofosbuvir and ledipasvir and of ombitasvir, paritaprevir, and ritonavir tablets co-packaged with dasabuvir tablets were also endorsed.